Terms: = Leukemia AND FUS, P35637, 2521, ENSG00000089280, TLS/CHOP, FUS-CHOP, CHOP, FUS1, TLS
865 results:
1. A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.
Manda S; Anz BM; Benton C; Broun ER; Yimer HA; Renshaw JS; Geils G; Berdeja J; Cruz J; Melear JM; Fanning S; Fletcher L; Li Y; Duan Y; Werner ME; Potluri J; Pai MV; Donnellan WB
Hematol Oncol; 2024 May; 42(3):e3274. PubMed ID: 38711253
[TBL] [Abstract] [Full Text] [Related]
2. Treatment patterns, clinical outcomes and gene mutation characteristics of hepatitis B virus-associated mantle cell lymphoma.
Feng J; Fei Y; Gao M; Meng X; Zeng D; Zou D; Ye H; Liang Y; Sun X; Liang R; Zhou H; Wang X; Zhang H
Hematol Oncol; 2024 May; 42(3):e3268. PubMed ID: 38676394
[TBL] [Abstract] [Full Text] [Related]
3. A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia.
Hampel PJ; Swaminathan M; Rogers KA; Parry EM; Burger JA; Davids MS; Ding W; Ferrajoli A; Hyak JM; Jain N; Kenderian SS; Wang Y; Wierda WG; Woyach JA; Parikh SA; Thompson PA
Blood Adv; 2024 May; 8(10):2342-2350. PubMed ID: 38537065
[TBL] [Abstract] [Full Text] [Related]
4. Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe study.
Schwaner I; Kuhn T; Losem C; Wolff T; Otremba B; Zaiss M; Hülsenbeck J; Famulla K; Nösslinger T; Rossi D
Ann Hematol; 2024 Jun; 103(6):2013-2020. PubMed ID: 38421404
[TBL] [Abstract] [Full Text] [Related]
5. A case of peripheral T-cell lymphoma in which therapy-related myelodysplastic syndrome developed and a second autologous transplantation was performed.
Nakagawa SI; Nukii Y; Mochizuki K; Uchiyama A; Maeda Y; Kurokawa T
J Clin Exp Hematop; 2024 Mar; 64(1):59-64. PubMed ID: 38417872
[TBL] [Abstract] [Full Text] [Related]
6. Venetoclax combined with decitabine induced tumor lysis syndrome in a young patient with acute myeloid leukemia: a case report and literature review.
Zhang H; Liu J; Wu Q; Xia L
Anticancer Drugs; 2024 Jun; 35(5):440-444. PubMed ID: 38386312
[TBL] [Abstract] [Full Text] [Related]
7. Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Lei MM; Sorial MN; Lou U; Yu M; Medrano A; Ford J; Nemec RA; Abramson JS; Soumerai JD
Leuk Lymphoma; 2024 May; 65(5):653-659. PubMed ID: 38293753
[TBL] [Abstract] [Full Text] [Related]
8. Management and use of healthcare resources in patients with chronic lymphocytic leukemia initiating venetoclax in routine clinical practice.
Banerji V; Aw A; Laferriere N; Abdel-Samad N; Peters A; Johnson NA; Bernard MP; Gopalakrishnan S; Bull SJ; Fournier PA; Klil-Drori AJ; Hay AE; Robinson S; Owen C
Leuk Lymphoma; 2024 May; 65(5):609-617. PubMed ID: 38235709
[TBL] [Abstract] [Full Text] [Related]
9. Genetic and transcriptomic analyses of diffuse large B-cell lymphoma patients with poor outcomes within two years of diagnosis.
Ren W; Wan H; Own SA; Berglund M; Wang X; Yang M; Li X; Liu D; Ye X; Sonnevi K; Enblad G; Amini RM; Sander B; Wu K; Zhang H; Wahlin BE; Smedby KE; Pan-Hammarström Q
Leukemia; 2024 Mar; 38(3):610-620. PubMed ID: 38158444
[TBL] [Abstract] [Full Text] [Related]
10. Renomegaly and acute kidney injury as primary manifestations of non-Hodgkin's lymphoma: a report of three cases.
Bai Y; Zheng Y; Zhang Q; Jiang Q; Diao Z; Guo W; Liu S; Liu W
Diagn Pathol; 2023 Dec; 18(1):133. PubMed ID: 38066507
[TBL] [Abstract] [Full Text] [Related]
11. Synergistic lethality in chronic myeloid leukemia - targeting oxidative phosphorylation and unfolded protein response effectively complements tyrosine kinase inhibitor treatment.
Häselbarth L; Gamali S; Saul D; Krumbholz M; Böttcher-Loschinski R; Böttcher M; Zou D; Metzler M; Karow A; Mougiakakos D
BMC Cancer; 2023 Nov; 23(1):1153. PubMed ID: 38012567
[TBL] [Abstract] [Full Text] [Related]
12. Spontaneous tumor lysis syndrome in a patient with chronic myeloid leukemia treated successfully with allopurinol.
Gartenberg A; Winkel M; Leonard N
Am J Emerg Med; 2024 Apr; 78():242.e1-242.e3. PubMed ID: 38007380
[TBL] [Abstract] [Full Text] [Related]
13. SOHO State-of-the-Art Updates and Next Questions: Treatment for Newly Diagnosed Peripheral T-Cell Lymphomas.
Burton JS; Foley NC; Mehta-Shah N
Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):65-76. PubMed ID: 37973458
[TBL] [Abstract] [Full Text] [Related]
14. Tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax and hypomethylating agents with or without dose ramp-up.
Khouderchah CJ; Benitez LL; Marini BL; Fraga M; Pettit K; Burke PW; Bixby DL; Perissinotti AJ
Leuk Lymphoma; 2024 Feb; 65(2):228-234. PubMed ID: 37933203
[TBL] [Abstract] [Full Text] [Related]
15. [Adult T-cell leukemia/lymphoma].
Yoshimitsu M
Rinsho Ketsueki; 2023; 64(9):1032-1040. PubMed ID: 37899180
[TBL] [Abstract] [Full Text] [Related]
16. Poor Outcome of Adult T-Cell leukemia/Lymphoma with Current Available Therapy: An Experience of Two Centers.
Saeed H; Sandoval-Sus J; Castillo-Tokumori F; Dong N; Pullukkara JJ; Boisclair S; Brahim A; Walker D; Bridgellal S; Zhang L; Sokol L
Oncol Res Treat; 2023; 46(11):459-465. PubMed ID: 37844559
[TBL] [Abstract] [Full Text] [Related]
17. Divergent CD4
Khelfa M; Leclerc M; Kerbrat S; Boudjemai YNS; Benchouaia M; Neyrinck-Leglantier D; Cagnet L; Berradhia L; Tamagne M; Croisille L; Pirenne F; Maury S; Vingert B
Front Immunol; 2023; 14():1165973. PubMed ID: 37701444
[TBL] [Abstract] [Full Text] [Related]
18. Mosunetuzumab in combination with chop in previously untreated DLBCL: safety and efficacy results from a phase 2 study.
Olszewski AJ; Phillips TJ; Hoffmann MS; Armand P; Kim TM; Yoon DH; Mehta A; Greil R; Westin J; Lossos IS; Munoz JL; Sit J; Wei MC; Yang A; Chen V; Purev E; Yee DL; Jaeger U
Blood Adv; 2023 Oct; 7(20):6055-6065. PubMed ID: 37581593
[TBL] [Abstract] [Full Text] [Related]
19. Real-world time to discontinuation of first-line venetoclax + obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma.
Lu X; Emond B; Qureshi ZP; Wu LH; Forbes SP; Hilts A; Liu S; Lafeuille MH; Lefebvre P; Huang Q; Rogers KA
Curr Med Res Opin; 2023 Sep; 39(9):1227-1235. PubMed ID: 37530387
[TBL] [Abstract] [Full Text] [Related]
20. Investigating the synergistic potential of TRAIL and SAHA in inducing apoptosis in MOLT-4 cancer cells.
Mohammad Mirzapour M; Farshdousti Hagh M; Marofi F; Solali S; Alaei A
Biochem Biophys Res Commun; 2023 Oct; 676():13-20. PubMed ID: 37480688
[TBL] [Abstract] [Full Text] [Related]
[Next]
